Laurie Keefer, PhD, is a clinical health psychologist and professor of medicine at Icahn School of Medicine at Mount Sinai.

Risankizumab’s 1 Year Improvement in HRQL and Wellbeing For Crohn’s Disease

1-year results from ASPIRE-CD suggest risankizumab (Skyrizi) may improve general well-being and health-related quality of life (HRQL) in adults with moderately to severely active 

 2026, including improvements in sexual health, work productivity, daily activity levels, life enjoyment, and treatment satisfaction 1 year after patients started taking risankizumab.

HRQoL, Treatment Satisfaction With Risakizumab in ASPIRE-CD, With Laurie Keefer, PhD


Addressing An Unmet Need in Crohn’s Disease With ASPIRE-CD

ASPIRE-CD is an ongoing, observational, prospective, longitudinal patient survey study evaluating real-world experiences of adults with moderately to severely active CD who are treated with risankizumab in clinical practice, with investigators citing the importance of these patient-centered outcomes.

“To rigorously measure fatigue, extra-intestinal manifestations, and the impact on sexual function was the first time that we were able to look at and ask about that. The fact that it was even measured systematically, proactively as part of the study, was a huge addition,” said study investigator and abstract presenter Laurie Keefer, PhD, a clinical health psychologist and professor of medicine, psychiatry, and biomedical sciences at the Icahn School of Medicine at Mount Sinai, in an interview with 

. “Often, those symptoms are pushed aside as not super important, or they're an afterthought.”

Before initiating risankizumab intravenously and after 52 weeks, APIRE-CD participants completed surveys addressing life enjoyment, the negative impact of CD on sexual interest/activity, and satisfaction with treatment, which were evaluated using a 4-week recall and Likert scales. Additional data collection included the Short Form (SF)-12 version 2 Health Survey and the Work Productivity and Activity Impairment Questionnaire: CD (WPAI: CD).

ASPIRE-CD included 286 patients, of which 74.5% completed the Week 52 survey (n = 213), and 86.4% remained on risankizumab (n = 184). The trial population was 57.0% female, had a mean age of 45 years, 90.2% were White, and 75.2% were biologic- or Janus kinase inhibitor-experienced.

At Week 52, 77.0% of patients reported improvement in life enjoyment since starting risankizumab:

Among patients indicating sexual interest/activity, the proportion who reported being at least somewhat satisfied with their sex life increased from 35.5% at baseline to 51.5% at Week 52 (

< .001). The proportion of patients reporting that CD had no negative impact on their sexual interest/activity increased from 31.6% to 51.2% (

Overall satisfaction with CD treatments improved from 50.0% at baseline

Investigators noted an increase to 86.9% among all survey completions:

Including a 92.4% among patients remaining on risankizumab at Week 52:

“When we push patients to take medications, they want you to set expectations. How long will it take for me to feel better? What should I be looking for? And with fatigue and pain, a little bit of relief early on can go a long way for patient optimism, hope for the future, and a sense of confidence about being able to manage it,” Keefer said. “That conversation, the shared decision making that goes on by being able to say 2 weeks, you know, might not be a perfect outcome, but you're going to start to feel better, is gold for patients.”

Investigators also observed significant improvements in the physical component summary of the SF-12v2 with a baseline of 46.2 [9.40] compared to a Week 52: 49.8 [9.4] (

<.001) and all domains of the WPAI through Week 52.

Editor’s Note: Keefer reports relevant disclosures with Ardelyx, Trellus Health, Fzata, AbbVie, and others.

Lauren Keefer. RISANKIZUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH CROHN'S DISEASE: YEAR 1 RESULTS FROM THE ASPIRE-CD STUDY. Poster presented at: Digestive Disease Week; May 2-5, 2026; Chicago, IL.

Keefer L. HRQoL, Treatment Satisfaction With Risakizumab in ASPIRE-CD, With Laurie Keefer, PhD. HCPLive. Published October 29, 2025. Accessed May 5, 2026. 

https://www.hcplive.com/view/hrqol-treatment-satisfaction-with-risakizumab-aspire-cd-with-laurie-keefer-phd

Videos

1-year results from ASPIRE-CD suggest risankizumab (Skyrizi) improves HRQL, well-being, and treatment satisfaction in adults with Crohn's Disease.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Risankizumab’s 1 Year Crohn's Disease Improvement in HRQL and Wellbeing in ASPIRE-CD

Physician and CEO, Chicago Allergy Center, and board director at American Lung Association

World Asthma Day 2026: Uncontrolled Disease and Racial Disparities Demand Structural Solutions, With Juanita Mora, MD

 affects an estimated 27 to 30 million Americans — with a substantial proportion remaining inadequately controlled despite available therapies — World Asthma Day 2026 offers an opportunity to reckon with the structural and systemic forces that are keeping effective treatment out of reach for the patients who need it most, according to Juanita Mora, MD.

Mora, an allergist-immunologist at Chicago Allergy Center and attending physician at Advocate Illinois Masonic Medical Center in Chicago, Illinois, emphasized that uncontrolled asthma in the United States is not primarily a treatment gap but an access and equity gap. The most striking illustration of that inequity is the racial disparity in asthma mortality: according to federal surveillance data, Black American adults are more than twice as likely to die from asthma compared with US adults overall, and Black American children are approximately 3 to 4 times more likely to die from asthma than their white peers — disparities that persist despite decades of therapeutic advances and that Mora characterized as preventable.

She identified several overlapping structural barriers driving these outcomes. Lack of health insurance remains a fundamental obstacle, leaving many patients without reliable access to prescription medications and specialist care. The cost of asthma medications — including both daily controller inhalers and biologic therapies for severe disease — is a second distinct barrier, one Mora noted she has been actively engaged in addressing through advocacy efforts. Geographic access to specialists is a third constraint: patients in many communities must travel 30 or more miles to reach an allergist or pulmonologist, or navigate insurance networks that severely limit specialist options. Language barriers in clinical settings add further complexity for non-English-speaking patients, particularly in Hispanic and other immigrant communities.

Mora outlined several mechanisms she sees as capable of materially reducing these barriers. Telehealth — which expanded substantially during the pandemic and has demonstrated utility in asthma management — allows specialists to reach patients who cannot travel, and she called for continued support for telehealth reimbursement policies that make this access sustainable. Expanded insurance coverage, including coverage for all patients regardless of immigration or income status, was framed as the most foundational change needed. On the technology side, she highlighted 2 developments she sees as particularly promising: ultra-long-acting biologic formulations that reduce the dosing frequency burden and may improve adherence in patients with limited health system touchpoints, and digital smart inhalers that track medication use in real time, allowing clinicians to identify adherence gaps and patients to recognize when controller therapy is being used inadequately.

Environmental determinants received explicit attention. Mora called for reduction in outdoor air pollutants — including ozone and particulate matter — as well as targeted indoor air quality interventions, particularly around household smoking. Both exposures are disproportionately concentrated in urban and lower-income communities, compounding the biologic susceptibility to poorly controlled asthma in precisely those populations that also face the greatest barriers to specialist access and affordable medication. She framed these environmental and structural factors not as background context but as core clinical determinants — ones that clinicians cannot address alone and that require coordinated policy and public health responses.

“I think world asthma day also calls for a day that we have to talk about health equity and disparities in health that we currently exist in the United States,” Mora said.

Mora has no relevant disclosures to report.

Office of Minority Health, US Department of Health and Human Services. Asthma and Black/African Americans. Updated 2025. Accessed May 2026. 

https://minorityhealth.hhs.gov/asthma-and-blackafrican-americans

Black Americans bear a disproportionate burden of asthma mortality, and clinicians and policymakers must address a number of factors to make meaningful progress.


Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Nicole Beaulieu Perez, PhD, RN, PMHNP-BC, an assistant nursing professor at NYU Rory Meyers College of Nursing

Monocyte Aging Links to Non-Somatic Depression Symptoms, With Nicole Perez, PhD

Depression heterogeneity may obscure biologically meaningful signals, but new data suggest monocyte-specific epigenetic aging could help differentiate symptom domains. In an interview with 

, Nicole Beaulieu Perez, PhD, RN, PMHNP-BC, an assistant nursing professor at NYU Rory Meyers College of Nursing, said the findings reinforce a central clinical reality: "Depression is not a monolith,” with distinct symptom profiles potentially reflecting different underlying mechanisms.

“We see all the time in practice how patients present with a variety of presentations,” Perez said. “We know there's over 200 possible combinations of symptoms that get us that disorder of depression. What's been less clear is how those presentations have been linked differentially to underlying biology. What goes with that is that we see all the time that patients respond differently to medications that target different mechanisms, even though they have the same diagnosis. This study…is consistent with what we're seeing in that we found that the epigenetic aging and monocytes using this new clock monocyte age acceleration showed differential associations when we looked at symptoms of depression that were considered non-somatic.”

Non-somatic symptoms include profound hopelessness and anhedonia. Meanwhile, the study did not show a link between monocyte age acceleration and somatic symptoms, including fatigue and the inability to fall asleep.

“When we actually drill down and look at a symptom resolution lens of what symptoms people are experiencing, we see biological differences, and specifically in this study, having to do with the accelerated aging of monocytes,” she added.

The study analyzed 440 participants from the Women’s Interagency HIV Study, including 261 women with HIV (mean age, 43.7 years), evaluating associations between epigenetic age acceleration (EAA) and depressive symptoms measured by the Center for Epidemiologic Studies Depression Scale (CES-D). Investigators compared a monocyte-derived clock (MonoDNAmAge) with a multi-tissue clock (HorvathDNAmAge), focusing on symptom domains rather than total scores.

In adjusted models, monocyte EAA was associated with non-somatic depressive symptoms (

=.018), with particularly strong associations for anhedonia (

=.007). No associations were observed for somatic symptoms such as fatigue or sleep disturbance at the domain level. Horvath-based EAA was not associated with total or domain-specific depressive symptoms.

Although the findings do not alter current diagnostic criteria for major depressive disorder (MDD), they support a more granular approach to symptom assessment. Perez noted that clinicians already differentiate symptom patterns in practice, but existing frameworks and tools may not adequately capture this heterogeneity.

She pointed to limitations of total scores from commonly used scales such as the CES-D. These instruments aggregate symptoms across multiple domains, despite depression being a multidimensional construct encompassing affective, cognitive, and somatic features.

“Someone could have the same score at 2 different time points but totally different symptoms,” Perez said. “It’s misleading to think that necessarily their symptoms are the same over time.”

Biomarker Potential and Biological Context

The study also advances interest in monocyte epigenetic aging as a potential biomarker for depression. However, its clinical role remains uncertain. Because the analysis was cross-sectional, it cannot determine whether monocyte EAA reflects a state marker of current symptom burden or a trait marker of vulnerability.

The findings may be particularly relevant for populations with elevated inflammatory burden. Women living with HIV experience greater rates of depression and chronic comorbidities, alongside social and structural stressors that may contribute to “biological weathering,” a process linking environmental adversity to accelerated aging.

The selective association between monocyte aging and non-somatic symptoms supports emerging models of depression subtypes, including inflammation-related phenotypes characterized by anhedonia and affective disturbance. By contrast, the absence of associations with somatic symptoms highlights the importance of domain-specific analyses. Overall, the study suggests that aligning biological measures with specific symptom dimensions may improve signal detection and advance precision psychiatry.

“I don't think it's ready for prime time yet,” Perez said. “What we're seeing here is that folks [who] have distinct presentations are going to have different biological mechanisms at play.”

Perez NB, Xu K, Xu Y, et al. Monocyte Epigenetic Age Acceleration is Linked to Non-Somatic Depressive Symptoms in Women with and Without HIV. 

In this interview, Perez discusses data linking monocyte epigenetic age acceleration to non-somatic depressive symptoms.


Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

The international Tokyo Guidelines 2018 recommend 4 to 7 days of antibiotic treatment after adequate biliary drainage, with observational data prompting investigators to conduct the non-inferiority COBRA trial to assess whether shorter treatment may be sufficient for adults with acute 

2026 show that 1 day of antibiotic therapy after adequate endoscopic biliary drainage was noninferior compared to 4 to 7 days in adults with acute cholangitis, with investigators suggesting 1 day should be the preferred duration of antibiotic treatment.

Background on Acute Cholangitis and Post- Adequate Biliary Drainage Duration of Antibiotic Treatment

If not treated promptly, acute cholangitis can lead to sepsis, with general hospital mortality for biliary sepsis around 21%, and even up to 40% in severe septic shock cases.

Study investigators describe the achievement of adequate biliary drainage by endoscopic retrograde cholangiopancreatography (ERCP) as the cornerstone of therapeutic management for acute cholangitis.

While the Tokyo Guidelines 2018 recommend an antibiotic duration of 4 to 7 days, contradicting guidelines have led to varying clinical practice decisions. For example, the Dutch national sepsis treatment guidelines state that an antibiotic treatment of 1 to 3 days is adequate after source control.

The variation across guidelines can lead to inconsistencies in clinical practice regarding the duration of antibiotic treatment, with time ranging from 1 to 13 days after ERCP.

To examine the range in antibiotic treatment duration, study investigators conducted a multicenter, open-label, parallel group randomized controlled non-inferiority trial in 31 hospitals in the Netherlands. The primary objective was to assess whether a short-course of antibiotic treatment, defined as 1 day, following adequate biliary drainage, is non-inferior to a longer course of antibiotic treatment, defined as 4 to 7 days, in achieving clinical cure.

Investigators defined the primary outcome as clinical cure, with a patient being free of symptoms by day 14 after ERCP, with no relapse or death occurring by day 30. The primary endpoint was adjudicated by an independent blinded committee. The intention-to-treat and per-protocol populations were analyzed, and the absolute risk difference for clinical cure was calculated. Investigators deemed that non-inferiority was demonstrated if the one-sided 95% confidence limit for the absolute risk difference was > -7.5%.

They randomly assigned 413 patients with acute cholangitis due to distal biliary obstruction who achieved adequate endoscopic biliary drainage and fever resolution within 24 hours after ERCP, in a 1:1 ratio, to receive antibiotics for 1 day (n = 205) or 4 to 7 days (n = 208) after ERCP.

The average age of COBRA’s patient population was 74 years, 43.4% were women, 10.0% had malignant obstruction, 57.6% had moderate/severe cholangitis, and 35.6% had gram-negative bacteraemia at the time of randomization. 3 patients in the 4 to 7 day group were lost to follow-up before the primary outcome could be assessed, excluding them from all analyses, and marking a 93.0% adherence to the allocated antibiotic treatment duration.

In the intention-to-treat analysis, investigators observed that the primary outcome occurred in 95.1% of patients (195/205) in the 1-day group compared to 93.7% in the 4 to 7 day group (192/205), with an absolute risk difference of 1.5% (one-sided 95% confidence limit: -2.4%), demonstrating non-inferiority.

A per-protocol analysis (n = 384) showed non-inferiority (absolute risk difference 0.6%, with one-sided 95% confidence limit: -3.2%). In a worst-case sensitivity analysis (with lost to follow-up counting as failures), non-inferiority was maintained. All-cause 30-day mortality was 2/205 in the 1-day group compared to 1/205 in the 4 to 7-day group.

Based on these results, investigators concluded that 1 day of antibiotic treatment after adequate endoscopic biliary drainage is non-inferior to 4 to 7 days in adults with acute cholangitis. Therefore, they suggest that 1 day should be the preferred duration of antibiotic treatment after adequate biliary drainage.

Overdevest AG, Sieswerda E, Haal S, et al. Antibiotic treatment for 1 day versus 4–7 days in patients with acute cholangitis after adequate endoscopic biliary drainage (COBRA): study protocol for a randomized controlled trial. 

https://doi.org/10.1186/s13063-026-09524-7

Anouk Overdevest. ONE DAY OF ANTIBIOTIC TREATMENT IS NON-INFERIOR TO 4 - 7 DAYS IN PATIENTS WITH ACUTE CHOLANGITIS AFTER ADEQUATE BILIARY DRAINAGE (COBRA): A MULTI-CENTER RANDOMIZED CONTROLLED TRIAL. Poster presented at: Digestive Disease Week; May 2-5, 2026; Chicago, IL.

Beliaev AM, Sof'ya Zyul'korneeva, Rowbotham D, Bergin CJ. Screening acute cholangitis patients for sepsis. 

Articles

Adequate source control via ERCP is central to acute cholangitis management, yet post-drainage antibiotic duration remains heterogeneous across guidelines and practice. In the multicenter, open-label COBRA non-inferiority RCT across 31 Dutch hospitals, 413 adults with distal biliary obstruction, successful endoscopic drainage, and fever resolution within 24 hours were randomized to 1 day versus 4–7 days of antibiotics. Clinical cure at day 14 without relapse/death by day 30 was comparable, meeting non-inferiority in intention-to-treat and per-protocol analyses.

COBRA findings suggest 1 day of antibiotic treatment is preferred in acute cholangitis after adequate biliary drainage compared to longer guidelines.


Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Hepatology

Shorter Antibiotic Treatment After Adequate Biliary Drainage Non-Inferior in Acute Cholangitis

Edward Barnes, MD, MPH, is an associate professor of medicine in the division of gastroenterology and hepatology and co-director of the Multidisciplinary Inflammatory Bowel Diseases Center at the University of North Carolina at Chapel Hill.

Mirikizumab After Anti-TNF Failure: New Crohn’s Disease Data Explained

 who have already cycled through first-line biologic therapy, treatment decisions become increasingly complex while the likelihood of achieving meaningful, durable remission often declines. As more advanced therapies enter the market, clinicians are left navigating which agents can still deliver strong outcomes after anti-TNF failure.

New data presented at Digestive Disease Week (DDW) 2026 in Chicago, IL, begin to address that question, offering insight into the performance of mirikizumab in a second-line setting. In an interview with HCPLive, Edward Barnes, MD, MPH, discussed findings from a post hoc analysis of the VIVID clinical trial program, focusing specifically on patients who had experienced failure of a single anti-TNF agent.

Mirikizumab Maintains Disease Clearance in UC Through 4 Years in LUCENT-3 Extension

As Barnes emphasized, this population closely reflects the patients seen in routine clinical practice: those with moderate to severe disease who often have fewer effective options remaining. Historically, treatment response tends to diminish with each subsequent line of therapy, underscoring the importance of identifying therapies that maintain efficacy beyond first-line use.

VIVID Trial Data Highlight Clinical and Endoscopic Efficacy

The present analysis drew from patients enrolled in VIVID-1 and its open-label extension, VIVID-2, who had failed 1 prior anti-TNF therapy and had not been exposed to other advanced treatments. Outcomes assessed included clinical remission based on the Crohn’s Disease Activity Index (CDAI) and endoscopic response over time.

Results demonstrated clear separation between mirikizumab and placebo. By week 12, patients receiving mirikizumab had already shown improvements in clinical response and patient-reported outcomes.

Of note, these gains deepened over time, with statistically significant differences observed at week 52. At that point, 44.0% of patients treated with mirikizumab achieved CDAI remission compared with 15.5% in the placebo group (

<.001). Endoscopic response rates followed a similar pattern, with 37.1% of mirikizumab-treated patients achieving response versus 6.9% of those receiving placebo (

Treat-to-Target Approach Reflected in “Treat-Through” Study Design

A key strength of the VIVID program, according to Barnes, is its “treat-through” design, which avoids treatment interruption and more closely mirrors real-world practice. This framework aligns with treat-to-target strategies in inflammatory bowel disease, where initial symptomatic improvement is followed by objective measures such as biomarker normalization and endoscopic healing.

“You see patients feel well first, and then over time, they achieve those deeper endpoints,” Barnes explained, noting that while some patients achieved early endoscopic response, the most robust outcomes emerged with continued therapy through one year.

“We saw patients feel well first, and then the longer we followed them on the therapy, they then met the other endpoints that we would expect,” Barnes said. “It's not to say that, you know, a quarter of patients weren't already hitting endoscopic response by that 12 week period, but the longer the patients were on therapy, they continued to feel well.”

Durable Remission Supports Long-Term Use of IL-23 Inhibition

Long-term data from VIVID-2 further reinforce the durability of response with mirikizumab. Among patients who achieved endoscopic response at week 52, the majority maintained benefit through 2 years. At week 104, 77.1% remained in clinical remission, while more than 80% sustained endoscopic response.

For clinicians, these findings provide an added layer of confidence, not only that mirikizumab can induce remission in a post–anti-TNF population, but that these responses are likely to persist with continued treatment.

Implications for Second-Line Treatment Sequencing in Crohn’s Disease

As the therapeutic landscape in Crohn’s disease continues to evolve, data like these help inform real-world decision-making. Mirikizumab’s demonstrated efficacy and durability in patients with prior anti-TNF exposure position it as a compelling second-line option, particularly in a setting where treatment attrition is common.

“These are important results for clinical practice, because often we're looking for data like this, how well does this match the patient that's going to walk in my door next and a clinical decision that I'm going to try to make?” Barnes said. “I think this is going to help people in their clinic with their clinical decision making.”

Editors’ note: Barnes reports relevant disclosures with AbbVie, Bristol-Meyers Squibb, Lilly, and Target RWE.

Gisbert JP, Ma C, Fantini MC, et al. MIRIKIZUMAB IS EFFICACIOUS IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE AFTER ONE PRIOR ANTI-TNF FAILURE. Presented at Digestive Disease Week (DDW) 2026; Chicago, IL; May 2–5, 2026.

Lilly. Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years. May 5, 2026. Accessed May 5, 2026. 

https://lilly.mediaroom.com/2026-05-05-Lillys-Omvoh-mirikizumab-mrkz-is-the-first-and-only-IL-23p19-to-demonstrate-durable-disease-clearance-in-ulcerative-colitis-through-four-years

Edward Barnes, MD, MPH, explains mirikizumab’s strong remission and durable response in Crohn’s disease patients after anti-TNF failure, supporting second-line use.

VIVID Post Hoc Analysis Supports Mirikizumab After Anti-TNF Failure in Crohn’s Disease

Maria Abreu, MD, is Executive Director of the F. Widjaja Inflammatory Bowel Disease Institute at Cedars-Sinai.

Maria Abreu, MD, breaks down efficacy and safety data for dual-target co-antibody JNJ-4804, offering a potential new option for heavily pretreated UC patients.

DUET-UC Data Highlight Potential of Dual-Pathway Targeting in Refractory Ulcerative Colitis

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Catch up on key clinician insights, major FDA decisions, groundbreaking trial results, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Type 2 Diabetes

Thyroid Disorders

8 Endocrinology Headlines You Missed in April 2026

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The phase 3 FUZION trial found guselkumab achieved increased fistula remission rates than placebo in perianal fistulizing Crohn's disease.

Guselkumab Shows Efficacy in Perianal Fistulizing Crohn's Disease in Phase 3 FUZION Trial

Updated results from the NordICC trial build upon previous 10 year findings and shed further light on once-only colonoscopy as a primary screening modality.

NordICC: Single Colonoscopy Cuts Colorectal Cancer Incidence but Not Mortality at 13 Years

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

In the ongoing JADE EXTEND trial, long-term treatment with abrocitinib led to sustained skin clearance and other improvements through 112 weeks.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Abrocitinib Therapy Effective in Patients with Atopic Dermatitis at 2 Years

JNJ-4804 phase 2b results showed higher week-48 remission rates in refractory ulcerative colitis and Crohn disease.

JNJ-4804 Phase 2b Data Show Higher Week-48 Remission in Refractory UC, Crohn Disease

Phase 4 dupilumab data show improvements in esophageal distensibility and disease-related structural changes and inflammation in the esophagus in EoE.

REMODEL: Dupilumab Improves Esophageal Distensibility in EoE at 24 Weeks

Long-term LUCENT-3 data show mirikizumab sustained disease clearance in ulcerative colitis through 4 years of treatment.

Stephanie Gold, MD, is an instructor of medicine at the Icahn School of Medicine at Mount Sinai and a gastroenterologist at the Mount Sinai Hospital.

Stephanie Gold, MD, explains prospective IBD-Metabolic Clinic data show GLP-1 RAs are safe and effective for weight management in IBD, with added benefits for bowel function and fatigue.

Strategic Alliance Partnership

Adding GLP-1 RA Therapy to Lifestyle Counseling Drives Weight Loss, Improves Outcomes in IBD

Catch up on 5 nephrology headlines you missed in April 2026, including WCN coverage, FDA updates, and trial data. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Latest News

Risankizumab’s 1 Year Crohn's Disease Improvement in HRQL and Wellbeing in ASPIRE-CD

World Asthma Day 2026: Uncontrolled Disease and Racial Disparities Demand Structural Solutions, With Juanita Mora, MD

Monocyte Aging Links to Non-Somatic Depression Symptoms, With Nicole Perez, PhD

Shorter Antibiotic Treatment After Adequate Biliary Drainage Non-Inferior in Acute Cholangitis

VIVID Post Hoc Analysis Supports Mirikizumab After Anti-TNF Failure in Crohn’s Disease